The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

ACMC-1C2XD     2-ethylamino-4-methyl-5,5- dioxo-5$l^{6},7...

Synonyms: AG-J-06837, SureCN3306381, CHEBI:101089, AC1L1FAK, AC1Q6UVC, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of dorzolamide

  • METHODS: According to a 4 x 4 Latin squares design for repeated measures, 27 untreated patients and patients with newly diagnosed primary open-angle glaucoma (POAG) were treated with timolol 0.5% at 8 AM and 8 PM; brimonidine 0.2% at 8 AM and 8 PM; dorzolamide 2% at 8 AM, 2 PM, and 8 PM; and latanoprost 0.005% at 8 PM [1].
  • Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension [2].
  • Because these processes may play a role in diabetic retinopathy, the authors undertook this study to investigate the protective action of dorzolamide, an inhibitor of carbonic anhydrase, on retinal neural cells [3].
  • RESULTS: Dorzolamide-treated eyes were not significantly different from placebo-treated eyes in corneal deswelling rate, expressed as the percent recovery per hour (55.7% +/- 13.6% versus 59.6% +/- 14.5%; P > or = 0.10), open eye steady state thickness, swelling induced by hypoxia, and corneal autofluorescence [4].
  • Nephrolithiasis with dorzolamide [5].

Psychiatry related information on dorzolamide


High impact information on dorzolamide


Chemical compound and disease context of dorzolamide


Biological context of dorzolamide


Anatomical context of dorzolamide


Associations of dorzolamide with other chemical compounds

  • To prove that the tail (in this case the pyridinecarboxylic moieties) conferring water solubility to a sulfonamide CA inhibitor is more important than the ring to which the sulfonamido group is grafted, we also prepared dorzolamide derivatives incorporating such moieties [19].
  • RESULTS: Intraocular pressure reduction was greater on average in the combination group than in the dorzolamide and timolol groups [20].
  • OBJECTIVE: To determine whether dosages of a selective beta-blocking agent (betaxolol) and a topical carbonic anhydrase inhibitor (dorzolamide), sufficient to significantly lower intraocular pressure (IOP), have similar or disparate impact on the retinal and retrobulbar circulation [21].
  • Patients receiving 2% pilocarpine had the highest rate of discontinuation due to a clinical adverse experience, and the use of dorzolamide was not associated with systemic side effects commonly observed with the use of oral carbonic anhydrase inhibitors [22].
  • PURPOSE: To evaluate the effect of dorzolamide 2% and latanoprost 0.005% on intraocular pressure (IOP) after small incision cataract surgery [23].

Gene context of dorzolamide

  • In order to prove that the tail (in this case the picolinoyl moiety) conferring water solubility to a sulfonamide CA inhibitor is critically important for its topical effectiveness, similarly to the ring to which the sulfonamido group is grafted, we also prepared a dorzolamide derivative to which the picolinoyl moiety was attached [24].
  • This new compound is more water soluble than dorzolamide (as hydrochloride salt), behaves as a strong CA II inhibitor and acts similarly to the parent derivative in lowering IOP in experimental animals [25].
  • Topiramate, ethoxzolamide and benzolamide showed subnanomolar hCA VII inhibitory activity, whereas acetazolamide, methazolamide, dorzolamide and brinzolamide showed K(I)-s in the range of 2.1-3.5 nM [26].
  • Furthermore, oral ACZ is reported to be more physiologically effective than 2% dorzolamide hydrochloride administered topically, even though in isolated tissues dorzolamide appears to be the most active as it shows the lowest IC(50) values for CA-II and CA-IV [M.F. Surgue, J. Ocular Pharmacol. Ther. 12 (1996) 363-376] [27].
  • The disposition of dorzolamide, a carbonic anhydrase-II (CA-II) inhibitor, was examined in rats after oral and iv administration of 0.05, 0.5, 5, and 25 mg/kg [28].

Analytical, diagnostic and therapeutic context of dorzolamide


  1. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Quaranta, L., Gandolfo, F., Turano, R., Rovida, F., Pizzolante, T., Musig, A., Gandolfo, E. Invest. Ophthalmol. Vis. Sci. (2006) [Pubmed]
  2. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Orzalesi, N., Rossetti, L., Invernizzi, T., Bottoli, A., Autelitano, A. Invest. Ophthalmol. Vis. Sci. (2000) [Pubmed]
  3. Inhibition of apoptosis and reduction of intracellular pH decrease in retinal neural cell cultures by a blocker of carbonic anhydrase. Kniep, E.M., Roehlecke, C., Ozkucur, N., Steinberg, A., Reber, F., Knels, L., Funk, R.H. Invest. Ophthalmol. Vis. Sci. (2006) [Pubmed]
  4. Effect of dorzolamide on corneal endothelial function in normal human eyes. Egan, C.A., Hodge, D.O., McLaren, J.W., Bourne, W.M. Invest. Ophthalmol. Vis. Sci. (1998) [Pubmed]
  5. Nephrolithiasis with dorzolamide. Carlsen, J., Durcan, J., Zabriskie, N., Swartz, M., Crandall, A. Arch. Ophthalmol. (1999) [Pubmed]
  6. Anorexia, depression and dementia induced by dorzolamide eyedrops (Trusopt). thoe Schwartzenberg, G.W., Trope, G.E. Can. J. Ophthalmol. (1999) [Pubmed]
  7. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Sugrue, M.F. Progress in retinal and eye research. (2000) [Pubmed]
  8. Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors. Nishimori, I., Minakuchi, T., Onishi, S., Vullo, D., Scozzafava, A., Supuran, C.T. J. Med. Chem. (2007) [Pubmed]
  9. Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% vs placebo in primary open-angle glaucoma and ocular hypertension subjects. Stewart, W.C., Day, D.G., Stewart, J.A., Holmes, K.T., Jenkins, J.N. Eye (London, England) (2004) [Pubmed]
  10. Development of a topical niosomal preparation of acetazolamide: preparation and evaluation. Aggarwal, D., Garg, A., Kaur, I.P. J. Pharm. Pharmacol. (2004) [Pubmed]
  11. Replacing maximum-tolerated medications with latanoprost versus adding latanoprost to maximum-tolerated medications: a two-center randomized prospective trial. Gandolfi, S.A., Rossetti, L., Cimino, L., Mora, P., Tardini, M., Orzalesi, N. Journal of glaucoma. (2003) [Pubmed]
  12. Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma. Ormrod, D., McClellan, K. Drugs & aging. (2000) [Pubmed]
  13. Twenty-four hour control of intraocular pressure with dorzolamide and timolol maleate in exfoliation and primary open-angle glaucoma. Konstas, A.G., Maltezos, A., Bufidis, T., Hudgins, A.G., Stewart, W.C. Eye (London, England) (2000) [Pubmed]
  14. Dorzolamide effect on ocular blood flow. Martinez, A., Gonzalez, F., Capeans, C., Perez, R., Sanchez-Salorio, M. Invest. Ophthalmol. Vis. Sci. (1999) [Pubmed]
  15. Clinical pharmacokinetics of dorzolamide. Martens-Lobenhoffer, J., Banditt, P. Clinical pharmacokinetics. (2002) [Pubmed]
  16. Population pharmacokinetics of 2% topical dorzolamide in the aqueous humor of humans. Schmitz, K., Banditt, P., Motschmann, M., Meyer, F.P., Behrens-Baumann, W. Invest. Ophthalmol. Vis. Sci. (1999) [Pubmed]
  17. Inhibition of carbonic anhydrase activity in cultured bovine corneal endothelial cells by dorzolamide. Srinivas, S.P., Ong, A., Zhai, C.B., Bonanno, J.A. Invest. Ophthalmol. Vis. Sci. (2002) [Pubmed]
  18. In vitro metabolism of dorzolamide, a novel potent carbonic anhydrase inhibitor, in rat liver microsomes. Hasegawa, T., Hara, K., Kenmochi, T., Hata, S. Drug Metab. Dispos. (1994) [Pubmed]
  19. Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring? Scozzafava, A., Menabuoni, L., Mincione, F., Briganti, F., Mincione, G., Supuran, C.T. J. Med. Chem. (1999) [Pubmed]
  20. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Boyle, J.E., Ghosh, K., Gieser, D.K., Adamsons, I.A. Ophthalmology (1999) [Pubmed]
  21. A comparative study of betaxolol and dorzolamide effect on ocular circulation in normal-tension glaucoma patients. Harris, A., Arend, O., Chung, H.S., Kagemann, L., Cantor, L., Martin, B. Ophthalmology (2000) [Pubmed]
  22. The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. The Dorzolamide Additivity Study Group. Strahlman, E.R., Vogel, R., Tipping, R., Clineschmidt, C.M. Ophthalmology (1996) [Pubmed]
  23. Effect of dorzolamide and latanoprost on intraocular pressure after small incision cataract surgery. Rainer, G., Menapace, R., Schmetterer, K., Findl, O., Georgopoulos, M., Vass, C. Journal of cataract and refractive surgery. (1999) [Pubmed]
  24. Carbonic anhydrase inhibitors. Part 71. Synthesis and ocular pharmacology of a new class of water-soluble, topically effective intraocular pressure lowering sulfonamides incorporating picolinoyl moieties. Supuran, C.T., Scozzafava, A., Menabuoni, L., Mincione, F., Briganti, F., Mincione, G. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. (1999) [Pubmed]
  25. Carbonic anhydrase inhibitors. Water-soluble, topically effective intraocular pressure lowering agents derived from isonicotinic acid and aromatic/heterocyclic sulfonamides: is the tail more important than the ring? Menabuoni, L., Scozzafava, A., Mincione, F., Briganti, F., Mincione, G., Supuran, C.T. J. Enzym. Inhib. (1999) [Pubmed]
  26. Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides. Vullo, D., Voipio, J., Innocenti, A., Rivera, C., Ranki, H., Scozzafava, A., Kaila, K., Supuran, C.T. Bioorg. Med. Chem. Lett. (2005) [Pubmed]
  27. Acetazolamide: future perspective in topical glaucoma therapeutics. Kaur, I.P., Smitha, R., Aggarwal, D., Kapil, M. International journal of pharmaceutics. (2002) [Pubmed]
  28. Nonlinear dorzolamide pharmacokinetics in rats: concentration-dependent erythrocyte distribution and drug-metabolite displacement interaction. Wong, B.K., Bruhin, P.J., Barrish, A., Lin, J.H. Drug Metab. Dispos. (1996) [Pubmed]
  29. Optic nerve oxygen tension in pigs and the effect of carbonic anhydrase inhibitors. Stefánsson, E., Jensen, P.K., Eysteinsson, T., Bang, K., Kiilgaard, J.F., Dollerup, J., Scherfig, E., la Cour, M. Invest. Ophthalmol. Vis. Sci. (1999) [Pubmed]
  30. Ultratrace analysis of drugs in biological fluids using affinity probe capillary electrophoresis: analysis of dorzolamide with fluorescently labeled carbonic anhydrase. Tim, R.C., Kautz, R.A., Karger, B.L. Electrophoresis (2000) [Pubmed]
  31. Studies on the mechanism of action of timolol and on the effects of suppression and redirection of aqueous flow on outflow facility. Kiland, J.A., Gabelt, B.T., Kaufman, P.L. Exp. Eye Res. (2004) [Pubmed]
WikiGenes - Universities